Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetazolamide Plus Standard Triple Regimen for H. Pylori Eradication
NCT02090738Phase 2
Key facts
- Status
- Withdrawn
- Start
- Mar 2014
- Primary completion
- Dec 2014
- Countries
- 1
- Sponsor
- Yonsei University
- Modality
- Small Molecules
- Drugs
- acetazolamide
- Conditions
- Helicobacter pylori infection
01
Overview
Phase 2, randomised, open-label trial of acetazolamide in Helicobacter pylori infection (2 arms), sponsored by Yonsei University. Primary endpoint: H. pylori eradication rate at 1 month. Planned start Mar 2014; status: withdrawn.
02
Design
2 arms- Study design
- RandomizedOpen-label
Acetazolamide group
Acetazolamide + Standard Triple Therapy
Standard regimen group
Standard Triple Therapy
03
Endpoints
Primary
H. pylori eradication rate
Beyond the preview
Go deeper on NCT02090738.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02090738.